window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 29, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Cancer immunotherapy

  • Drug discovery,Oncology,Partnerships & Funding,Pharmaceuticals and therapeutics,Precision medicine,Research & Development,Technology and platforms

    Regeneron enters radiopharmaceuticals through multi-programme collaboration with Telix in oncology expansion

    Regeneron Pharmaceuticals has entered the radiopharmaceuticals field through a multi-programme [...]

    April 18, 2026
  • Clinical Trials,Immunology,Oncology,Research & Development

    Kainova expands Phase 1/2 trial of DT-7012 with first European patient dosed

    Kainova Therapeutics has dosed the first European patient in its [...]

    April 10, 2026
  • Clinical Development,Clinical Trials,Immunology,Oncology,Pharmaceuticals and therapeutics

    Scancell clears FDA IND for iSCIB1+ registrational Phase 3 trial in advanced melanoma

    Scancell Holdings has announced that the U.S. Food and Drug [...]

    January 26, 2026
  • Clinical Development,Clinical Trials,Movers & Shakers,Oncology,Research & Development

    Syncromune appoints Stephen Dale as Chief Medical Officer

    Syncromune has appointed Stephen Dale as chief medical officer, strengthening [...]

    January 14, 2026
  • CDMOs & Manufacturing,Clinical Development,Manufacturing,Market Access & Commercialization,Oncology

    Symbiosis manufactures first commercial-scale batch at new Stirling facility

    Symbiosis Pharmaceutical Services has completed its first commercial-scale manufacturing run [...]

    January 5, 2026
  • Biotech,Market Access & Commercialization,Oncology,Partnerships & Funding,Research & Development

    Cue Biopharma and ImmunoScape partner on novel in vivo cell therapy for solid tumours

    Cue Biopharma and ImmunoScape have entered an exclusive collaboration and [...]

    November 6, 2025
  • Biologics & Biosimilars,Biotech,Chronic diseases,Clinical Development,Oncology,Pharmaceuticals and therapeutics,Research & Development

    Enterome’s EO2463 receives FDA fast track designation for follicular lymphoma watch-and-wait treatment

    Enterome has received Fast Track designation from the US Food [...]

    October 17, 2025
  • Biologics & Biosimilars,Clinical Trials,Oncology,Pharmaceuticals and therapeutics,Rare Diseases,Research & Development

    Poolbeg secures free supply of bispecific antibody for POLB 001 trial at The Christie

    Poolbeg Pharma has appointed Accelerating Clinical Trials (ACT) to run [...]

    September 25, 2025
  • Clinical Development,Movers & Shakers,Oncology,RNA Therapeutics

    Strand Therapeutics appoints Jason Luke as chief medical officer

    Strand Therapeutics has appointed oncology researcher Jason Luke as its [...]

    August 26, 2025
  • Artificial Intelligence,Oncology,Precision medicine

    Biostate AI expands RNA-based precision medicine with new partnerships across China, India and the US

    Global collaborations boost dataset powering AI diagnostics for cancer, cardiovascular [...]

    July 24, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • ISS National Lab research advances DNA-inspired cancer nanomaterials for chemotherapy and immunotherapy development
    Categories: Drug Delivery & Formulation, Drug Development, Oncology, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top